November 11, 2025
Who guards the price police?
PBM Drug Pricing Distortion Report
When the price police sell the pills: users say it’s not “complicated”
TLDR: A new report spotlights PBMs—price middlemen—owning drug makers and setting list prices, keeping a controversial pricing distortion alive. Commenters say it’s simple: profits and vertical integration reward price manipulation, with memes dunking on PBMs’ “lower the list price” PR while patients ask why their bills keep climbing.
PBMs—pharmacy benefit managers, the supposed middlemen who keep drug prices in check—are now owning drug companies and setting list prices, and the internet is screaming. The report calls this distortion “alive,” and the thread immediately roared with “so who’s guarding the price police?” energy. One user, quoting the authors’ “lots of cooks in the kitchen” line, snapped back: profits are double digits, it’s not complicated. Another summed it up like a crime drama: the system rewards price manipulation, vertical integration inflates sticker prices, competition shrinks, and voilà—Americans pay more.
The community dragged the PBM trade group’s lowerthelistprice.com as corporate cosplay: “lower the list price… for everyone else.” Meanwhile, references to PBM-owned labels like Quallent had commenters meme-ing PBM as “Please Bill More.” Data nerds linked the SSRN paper and Adam Fein’s question about PBM-owned list prices, while cynics said this “extinction-level distortion” never died—just got better at hiding behind integration.
There’s drama over blame: some point at Big Pharma’s fat margins, others say PBMs set the stage by nudging list prices for rebates and control. Mods got looped in after a reworded, punchy title, because even the headline became part of the chaos. Verdict from the crowd: the fox owns the henhouse—and sells the eggs.
Key Points
- •The article examines pricing incentives when PBMs own drug manufacturers, potentially blurring roles between price-fighters and price-setters.
- •PCMA is cited as claiming drug companies set and raise list prices, and it promotes lower list prices via lowerthelistprice.com.
- •Prior research by 46brooklyn analyzed reported end costs for Quallent Pharmaceuticals’ medicines across Medicaid, Medicare, and commercial markets.
- •The authors note that list prices often diverge from true costs and payer experiences, limiting their value as affordability indicators.
- •A new analysis is announced to compare list prices for PBM-affiliated drug companies versus standalone manufacturers to assess alignment with PBM claims.